- READ MORE: Could harmful air be increasing your risk of dementia? UK's areas with high pollution levels
A revolutionary new medication may stop the advancement ofAlzheimer's disease, claim researchers.
Studies indicate that the medication—known as trontinemab—may be the strongest tool available to combat dementia, delaying the advancement of the memory-destroying condition.
Researchers will now evaluate if the vaccine could be administered to individuals who have not yet received a diagnosis of the condition, in an effort to prevent symptoms from emerging in the future.
As per findings shared at the Alzheimer's Association International Conference in Toronto, the 'game-changing' therapy can remove the harmful plaque believed to cause Alzheimer's symptoms more quickly than any other approved medication.
The scientists characterized the results as "highly encouraging," noting that the medication produced significantly fewer adverse effects compared to current treatments.
Professor Sir John Hardy, head of neurological disease at University CollegeLondon, told The Telegraph: 'There is no question this could be revolutionary.'
It rapidly removes plaque from the brain, significantly quicker than what we have observed with [existing medications] lacanemab or donanemab.
In the ongoing trial, 90 percent of patients who were given the medication saw the removal of amyloid—a harmful protein that can create deposits and tangled structures in the brain, disrupting memory functions—within 28 weeks of beginning the therapy.
According to specialists, this indicates that the visible signs of the illness have vanished.
After an 18-month follow-up, scientists anticipate that these biological changes may lead to better memory and decision-making abilities, with 1,600 participants involved in the study.
Approximately one million individuals in the UK are believed to be affected by dementia, with Alzheimer's being the most prevalent type.
A recent study conducted by the Alzheimer's Society suggests that the total yearly cost of dementia in the UK amounts to £42 billion, with families shouldering the majority of the burden.
An aging population indicates that these expenses, which involve the lost income of informal caregivers, are expected to rise to £90 billion over the next 15 years.
However, specialists believe that if administered early enough, the medication might stop Alzheimer's completely, preventing certain patients from ever experiencing symptoms.
"We hope that by administering these medications to individuals at an early stage, we can prevent the disease's advancement before any symptoms appear," said Prof Hardy, who was the first to recognize the significance of amyloid in the condition.
Moreover, as the drug can more readily pass through the blood-brain barrier compared to existing therapies, it may produce strong results even at small amounts, allowing it to be sold at a significantly reduced cost.
Alongside the absence of adverse effects, this may lead to the medication being the first Alzheimer's therapy to receive funding from the NHS, according to specialists.
Professor Hardy added, "The findings indicate it is significantly faster and more secure than earlier medications, meaning reduced supervision."
That significantly reduces the cost, implying fewer MRI scans, which would certainly lead to NICE [National Institute of Health and Care Excellence] approval.
Last year, health regulators in the UK approved two so-called 'wonder' medications, lacanemab and donanemab, which specialists say may help slow the progression of the memory-eroding condition in its initial phases.
Both medications utilize antibodies to remove harmful plaques in the brain—but some specialists have cautioned that donanemab might lead tolife-threatening brain bleedsin one third of cases.
This new medication seems significantly safer, according to researchers, as fewer than five percent of participants experienced issues during the second stage of testing.
Professor Jonathan Schott, the chief medical officer at Alzheimer’s Research UK, stated: 'The data regarding trontinemab is highly encouraging, indicating that the medication can efficiently and quickly remove amyloid from the brain, with minimal adverse effects.'
We must now determine if these initial findings hold up in subsequent clinical trials, which are set to begin later this year, including in the UK.
These studies will determine if the medication is not just secure, but also affects memory, cognition, and overall well-being.
Levi Garraway, the chief medical officer at the manufacturing company Roche, stated: 'We are progressing science with the aim of postponing – and eventually stopping – the development of this severe illness, as we prepare for phase three trials in both early symptomatic and preclinical Alzheimer’s disease.'
Read more